言語を選択

TrkC

TrkC 詳細

英語名	Neurotrophic tyrosine kinase receptor type 3	市販薬剤の数	4
治験薬の数	6	ターゲットの別称	NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
研究＆開発段階	Approved

英語名	Neurotrophic tyrosine kinase receptor type 3
ターゲットの別称	NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
市販薬剤の数	4
治験薬の数	6
研究＆開発段階	Approved

TrkC 製品リスト

属性
Protein (1)Cell (1)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
Fc Tag (1)Tag Free (1)
マーカー
Unconjugated (1)- (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
CHEK-ATP189	Human	HEK293	HEK293/Human TrkC Stable Cell Line
TRC-H5256	Human	HEK293	Human TrkC / NTRK3 Protein, Fc Tag (MALS verified)

総数量2

TrkCバックグランド

Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene. It belongs to the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC). TrkC is the high affinity catalytic receptor for the neurotrophin NT-3 (neurotrophin-3). As such, TrkC mediates the multiple effects of this neurotrophic factor, which includes neuronal differentiation and survival.

TrkC分子の別称

NT-3 growth factor receptor,GP145-TrkC,Neurotrophic tyrosine kinase receptor type 3, TrkC tyrosine kinase

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Lestaurtinib	SPM-924; A-154475.0; KT-5555; SP-924; CEP-701	Phase 3 Clinical	Kyowa Hakko Kirin Co Ltd	Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential	詳細
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours	詳細
FCN-011	FCN-011	Phase 2 Clinical		Solid tumours	詳細
Emzeltrectinib	CT-3417; TQB-3558	Phase 1 Clinical	Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd	Solid tumours	詳細
HG-030	HG-030	Phase 1 Clinical	Hitgen Inc	Solid tumours	詳細
Paltimatrectinib	PBI-200	Phase 1 Clinical	Pyramid Biosciences	Brain Neoplasms; Desmoplastic Small Round Cell Tumor; Solid tumours	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Taletrectinib Adipate	DS-6051b; DS-6051a; DS-6051; AB-106; IBI-344	Approved	Daiichi Sankyo Co Ltd	达伯乐, DOVBLERON, IBTROZI	Mainland China	Carcinoma, Non-Small-Cell Lung	AnHeart Therapeutics Co Ltd	2024-12-17	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Neoplasms; Solid tumours	詳細
Entrectinib	NMS-E628; RXDX-101; RG-6268	Approved	Nerviano Medical Sciences Srl	Rozlytrek, 罗圣全	Japan	Carcinoma, Non-Small-Cell Lung	Chugai Pharmaceutical Co Ltd	2019-06-18	Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Thyroid Cancer, Papillary	詳細
Larotrectinib sulfate	LOXO-101; ARRY-470; BAY-2757556	Approved	Array Biopharma	Vitrakvi, 维泰凯	United States	Solid tumours	Bayer Healthcare	2018-11-26	Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fibrosarcoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile	詳細
Repotrectinib	TPX-0005; BMS-986472; ZL-2308	Approved	Turning Point Therapeutics Inc	Augtyro, 奥凯乐	United States	Carcinoma, Non-Small-Cell Lung	Bristol-Myers Squibb Company	2023-11-15	Brain metastases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Neoplasms; Solid tumours	詳細